PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA

Detalles Bibliográficos
Autores principales: Palacio, Melisa, Verstovsek, Srdan, Uno, Tomonori, Yamashita, Taishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428965/
http://dx.doi.org/10.1097/01.HS9.0000975672.66076.c4
_version_ 1785090597574410240
author Palacio, Melisa
Verstovsek, Srdan
Uno, Tomonori
Yamashita, Taishi
author_facet Palacio, Melisa
Verstovsek, Srdan
Uno, Tomonori
Yamashita, Taishi
author_sort Palacio, Melisa
collection PubMed
description
format Online
Article
Text
id pubmed-10428965
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104289652023-08-17 PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA Palacio, Melisa Verstovsek, Srdan Uno, Tomonori Yamashita, Taishi Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428965/ http://dx.doi.org/10.1097/01.HS9.0000975672.66076.c4 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Palacio, Melisa
Verstovsek, Srdan
Uno, Tomonori
Yamashita, Taishi
PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
title PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
title_full PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
title_fullStr PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
title_full_unstemmed PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
title_short PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
title_sort pb2232: a randomized, controlled clinical trial (phase 2b) of ns-018 versus best available therapy in subjects with primary or secondary myelofibrosis with severe thrombocytopenia
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428965/
http://dx.doi.org/10.1097/01.HS9.0000975672.66076.c4
work_keys_str_mv AT palaciomelisa pb2232arandomizedcontrolledclinicaltrialphase2bofns018versusbestavailabletherapyinsubjectswithprimaryorsecondarymyelofibrosiswithseverethrombocytopenia
AT verstovseksrdan pb2232arandomizedcontrolledclinicaltrialphase2bofns018versusbestavailabletherapyinsubjectswithprimaryorsecondarymyelofibrosiswithseverethrombocytopenia
AT unotomonori pb2232arandomizedcontrolledclinicaltrialphase2bofns018versusbestavailabletherapyinsubjectswithprimaryorsecondarymyelofibrosiswithseverethrombocytopenia
AT yamashitataishi pb2232arandomizedcontrolledclinicaltrialphase2bofns018versusbestavailabletherapyinsubjectswithprimaryorsecondarymyelofibrosiswithseverethrombocytopenia

Ejemplares similares